Trikafta™ is a highly effective therapy for the underlying cause of cystic fibrosis. It is approved for use in people with CF ages 12 and older who have at least one copy of the F508del mutation.
This page will be updated with new information as it becomes available.
- CF Foundation Celebrates FDA Approval of Triple Combination (English | Español)
- Trikafta™ Approval: Community Frequently Asked Questions (English | Español)
-
Recording of Trikafta Community Q&A Webinar: Michael Boyle, MD, SVP of Therapeutics Development, Mary Dwight, SVP of Policy and Advocacy, and Bruce Marshall, MD, SVP of Clinical Affairs, discuss the research behind the triple-combination therapy, questions around access, and how this breakthrough is expected to impact the health of those approved for the drug.